Search
Close this search box.

Elixirgen’s full-length dystrophin gene therapy, Insilico’s TNIK inhibitor and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

March 9, 2024 2:38 AM UTC

Elixirgen showed it was able to deliver a linear mRNA encoding a full-length human dystrophin protein, avoiding concerns that miniaturized versions of the gene may lack some critical functionality.

Most of the Duchenne muscular dystrophy (DMD) gene therapies in development deliver only a portion of the dystrophin gene, since it is too large to fit in a conventional adeno-associated viral (AAV) vector.  Elixirgen Therapeutics Inc.’s full-length version was delivered via a nanoparticle, and it restored muscular function in a mouse model of Duchenne muscular dystrophy, as shown at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference…